Frequencies of the most common genomic alterations reported in this study are consistent with results of previously published analyses in larger HR+ HER2- BC patient series [3,26,27] thus supporting the reliability of our methodology and the representativeness of our clinical cohort. Here, ERBB2 is linked to breast cancer.